KanawatTH/iStock via Getty Images Tesla, Inc. ( TSLA ) has seen a major downward revaluation so far in 2026, which was in part driven by a decline in financial expectations amid delivery challenges in the firm’s core market. As a result, investors expected a serious inventory buildup for the first-quarter for Tesla which was aided by the U.S. government eliminating federal tax subsidies for the pu...
KanawatTH/iStock via Getty Images Tesla, Inc. ( TSLA ) has seen a major downward revaluation so far in 2026, which was in part driven by a decline in financial expectations amid delivery challenges in the firm’s core market. As a result, investors expected a serious inventory buildup for the first-quarter for Tesla which was aided by the U.S. government eliminating federal tax subsidies for the purchase of an electric vehicle in the third-quarter of 2025. While Tesla did in fact see a significant buildup in the first-quarter, of about 50,000 units, the EV maker is adjusting its manufacturing processes and Tesla's CEO Elon Musk is guiding for a strategic shift towards autonomous mobility and AI-first robotics. I believe investors have become too bearish on Tesla’s growth prospects and I view the current consolidation as an excellent opportunity to increase exposure to Tesla ahead of the first-quarter earnings report. Data by YCharts Previous rating I rated shares of Tesla a Sell in my last coverage in February -- The Valuation Makes No Sense -- shortly after the firm’s Q1 ’26 earnings report because the EV platform remained, despite delivery challenges, widely profitable and published respectable gross margins. In the first-quarter, Tesla will likely have experienced a compression of its automotive gross margins -- a key figure for EV manufacturers -- and pressure on its free cash flow given Tesla’s production and delivery imbalance in the first-quarter. However, I feel that the recent negativity surrounding Tesla has become a little too much and the market is now, ahead of the Q1 '26 report on April 22nd , pricing in excessive levels of pessimism. Given the serious contraction in the valuation multiplier and sentiment change, I am changing my rating to buy, mainly because shares have reached my previous "buy level." Delivery-production imbalance set to pressure FCF and margins in Q1’26 Despite delivery headwinds in the market, Tesla reclaimed the title of the world'...
DKosig/iStock via Getty Images “Be careful what you wish for, lest it come true.” —Aesop Why didn't we do better when value outperformed? For several quarters, we've highlighted that market gains have been dominated by momentum and growth. Stocks that were rising kept rising, while laggards fell further behind. This created a historically wide gap in P/E multiples between our portfolio and the S&P...
DKosig/iStock via Getty Images “Be careful what you wish for, lest it come true.” —Aesop Why didn't we do better when value outperformed? For several quarters, we've highlighted that market gains have been dominated by momentum and growth. Stocks that were rising kept rising, while laggards fell further behind. This created a historically wide gap in P/E multiples between our portfolio and the S&P 500—and, more importantly, left Oakmark Fund's P/E well below even that of the Russell 1000 Value Index. Our conclusion was straightforward: since we were “more value” than the value indices, Oakmark should shine when the Russell Value eventually outperformed the S&P. It finally outperformed last quarter: the S&P 500 declined more than 4% while the Russell 1000 Value rose by over 2%. Did Oakmark outperform the value index as expected? No. We did better than the S&P but still declined. What happened? Typically, when the Russell Value outperforms, it's because low P/E stocks beat high P/E stocks. Since we believed the premium investors were paying for high-growth companies exceeded what fundamentals justified, we expected lower P/E stocks to outperform. But that's not what occurred last quarter. To understand why, consider how the Russell 1000 Growth and Value indices are constructed. Companies are ranked by price-to-book and expected two-year growth. Lower price and growth are called value; higher price and growth are called growth. The top 50% of market cap becomes the growth index, and the rest becomes the value index (with some companies in both). Because higher-growth stocks have recently outperformed, the number of companies in the growth index has shrunk. As a result, many high multiple, above-average growth businesses have been pushed into the value index. These higher-growth, higher-P/E stocks drove the Russell Value's strong first-quarter performance. For example, the Index's semiconductor-related stocks, which ended 2025 with an average forward P/E of 29, increase...
Circle 公司首席执行官杰里米·阿莱尔（Jeremy Allaire）近日回应了外界对其公司处理非法资金方式的批评，并就近期Drift Protocol遭黑客攻击事件中USDC未被冻结的争议进行了辩护。 阿莱尔在首尔举行的新闻发布会上强调，Circle是一家受监管的金融企业，严格遵循法治原则，只能在执法机构或法院的指令下冻结钱包。他表示，私自决定冻结将构成“重大道德困境”，不应由一家私营企业自...
Circle 公司首席执行官杰里米·阿莱尔（Jeremy Allaire）近日回应了外界对其公司处理非法资金方式的批评，并就近期Drift Protocol遭黑客攻击事件中USDC未被冻结的争议进行了辩护。 阿莱尔在首尔举行的新闻发布会上强调，Circle是一家受监管的金融企业，严格遵循法治原则，只能在执法机构或法院的指令下冻结钱包。他表示，私自决定冻结将构成“重大道德困境”，不应由一家私营企业自行判断该冻结哪些资金。 本月早些时候，去中心化金融协议Drift Protocol遭遇约2.8亿美元的大规模黑客攻击，其中约2.3亿美元的USDC被盗资金通过Circle的跨链传输协议在六小时内从Solana转移至以太坊，而Circle在此期间未采取冻结措施。这一事件引发了链上侦探ZachXBT等人士的公开批评。 阿莱尔承认当前法律框架存在缺口，并表示Circle正与美国立法机构就《CLARITY法案》进行沟通，寻求在极端情况下为稳定币发行方建立“安全港”机制，使其能够预防性地冻结资金，但强调相关授权必须以立法形式明确，而非由公司自行决定。 责任编辑：张俊 SF065
(RTTNews) - After recovering from an early move to the downside, treasuries showed a lack of direction for much of the trading day on Monday before eventually closing moderately higher.
(RTTNews) - After recovering from an early move to the downside, treasuries showed a lack of direction for much of the trading day on Monday before eventually closing moderately higher.
Rigetti Computing (NASDAQ: RGTI) is a promising tech company with loads of potential in the quantum computing space. As demand for artificial intelligence grows, so too does the need to process a lot of data quickly. If Rigetti develops computers that can help meet those needs, it can easily be a business that grows significantly in value. Unfortunately, that's still a long-term vision which could...
Rigetti Computing (NASDAQ: RGTI) is a promising tech company with loads of potential in the quantum computing space. As demand for artificial intelligence grows, so too does the need to process a lot of data quickly. If Rigetti develops computers that can help meet those needs, it can easily be a business that grows significantly in value. Unfortunately, that's still a long-term vision which could be years away from being a reality. In the meantime, the company is burning through cash, incurring losses, and it doesn't generate much growth these days. And its poor financials raise concerns about its long-term viability, which are undoubtedly weighing on its stock performance. This year, shares of Rigetti have declined by more than 30%. Have they bottomed out, and could now be a good time to buy the stock? Continue reading
sitox/E+ via Getty Images Almonty Industries ( ALM ) up 15.3% in Monday's trading after announcing it is moving its headquarters from Toronto to Dillon, Montana, to better reflect its strategic alignment with the U.S. "and its role in supporting secure, transparent, and Western-aligned supply chains for critical materials." The company said the move positions it closer to key stakeholders, includi...
sitox/E+ via Getty Images Almonty Industries ( ALM ) up 15.3% in Monday's trading after announcing it is moving its headquarters from Toronto to Dillon, Montana, to better reflect its strategic alignment with the U.S. "and its role in supporting secure, transparent, and Western-aligned supply chains for critical materials." The company said the move positions it closer to key stakeholders, including U.S. government agencies, defense contractors and industrial partners, while reinforcing its commitment to becoming the leading U.S.-aligned tungsten producer. The move also follows Almonty's ( ALM ) Nasdaq listing and US$90M IPO in July, a US$129M follow-on financing in December, and the acquisition of Montana's Gentung tungsten project, expected to restart production this year. Tungsten is a high-density metal used in defense systems, aerospace components, electronics and industrial tools, and Almonty ( ALM ) is one of the world's few suppliers of the metal outside of China. More on Almonty Industries Almonty Industries: Ride The Tungsten Supercycle Financial information for Almonty Industries
anyaivanova/iStock via Getty Images Kymera Therapeutics Overview The last time I wrote an article on Kymera Therapeutics ( KYMR ) it was with a Seeking Alpha article entitled " Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data ." With respect to this article, I mentioned that the company was gearing up to report results from its BroADen Phase 1b trial using oral STAT6 degrad...
anyaivanova/iStock via Getty Images Kymera Therapeutics Overview The last time I wrote an article on Kymera Therapeutics ( KYMR ) it was with a Seeking Alpha article entitled " Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data ." With respect to this article, I mentioned that the company was gearing up to report results from its BroADen Phase 1b trial using oral STAT6 degrader KT-621 for the treatment of patients with Atopic Dermatitis [AD]. I had given this stock a "Strong Buy" at that time, and I believe that it is important to maintain this rating yet again. Why is that? There are actually several reasons and developments that lead me to do so. The first of which is that the company did indeed report positive results from the phase 1b BroADen study using KT-621 to treat these AD patients. Specifically, there was a mean 63% EASI reduction and a mean 40% peak pruritus NRS reduction for all the patients who ended up receiving either 100 mg or 200 mg of this drug and who were treated for a total of 28 days [14 days of follow-up]. Based on this positive data, there were two other new developments relating to this program, the first of which is that the company received Fast Track Designation [FTD] from the FDA for KT-621 for the treatment of patients with AD. The second of which is that it is evaluating the use of this drug in the next clinical study, which is the phase 2b BROADEN2 study targeting this group of patients. The milestone to keep an eye out for in this program would be the release of data from the BROADEN2 trial in mid-2027. This alone would be enough to maintain this "Strong Buy" rating, but what I'm about to go over below is the fact that it might have an expansion opportunity on its hands because of the mode of action of this oral STAT6 protein degrader. This would be in terms of the fact that in Q1 of 2026 it did indeed initiate a study to evaluate the use of it in the phase 2b BREADTH trial for the treatment of patients with mo...
Gladstone Capital (NASDAQ:GLAD) does not behave like a typical business development company. Where many BDC peers chase yield through aggressive leverage and equity-heavy portfolios, Gladstone Capital leans on secured debt, conservative leverage, and a lower middle market focus that has historically produced steadier returns than the headline yield alone suggests. How Gladstone Capital Generates I...
Gladstone Capital (NASDAQ:GLAD) does not behave like a typical business development company. Where many BDC peers chase yield through aggressive leverage and equity-heavy portfolios, Gladstone Capital leans on secured debt, conservative leverage, and a lower middle market focus that has historically produced steadier returns than the headline yield alone suggests. How Gladstone Capital Generates Income ... Gladstone Capital’s 10% yield comes with a hidden strength: dividend coverage that actuall
KeyBanc Capital Markets认为T-Mobile将重回一年未见的价格水平，并认为现在是入手该股的时机。 这家投资银行在周日的一份报告中将其对这家电信公司的评级从“行业权重”上调至“增持”。分析师布兰登·尼斯佩尔设定的目标价为260美元，这意味着较上周五收盘价有近33%的上涨空间。尼斯佩尔写道，有机盈利增长加速、固定无线接入和移动业务的份额增长优势以及强劲的资产负债表应会推动股价走...
KeyBanc Capital Markets认为T-Mobile将重回一年未见的价格水平，并认为现在是入手该股的时机。 这家投资银行在周日的一份报告中将其对这家电信公司的评级从“行业权重”上调至“增持”。分析师布兰登·尼斯佩尔设定的目标价为260美元，这意味着较上周五收盘价有近33%的上涨空间。尼斯佩尔写道，有机盈利增长加速、固定无线接入和移动业务的份额增长优势以及强劲的资产负债表应会推动股价走高。 “鉴于估值相对于历史水平和同行有所压缩，我们认为存在合理的下行保护，”尼斯佩尔写道。“虽然我们不否认竞争加剧（ 威瑞森 /Starlink），但我们认为这两者都不会改变T-Mobile的发展轨迹。” 尼斯佩尔补充说，他认为公司定于4月28日发布的第一季度财报将带来业绩超预期和指引上调，这可能成为该股上涨的催化剂。 责任编辑：张俊 SF065
Jonathan Kitchen/DigitalVision via Getty Images By Peter C. Earle Household costs are rising faster than mainstream inflation gauges reveal. US military adventurism is hitting Americans hard. AIER’s proprietary Everyday Price Index (EPI) vaulted 2.5 percent to 307.4 in March 2026, its second-largest monthly increase back to January 2020 (the first was an increase of 2.9 percent in March 2022). Of ...
Jonathan Kitchen/DigitalVision via Getty Images By Peter C. Earle Household costs are rising faster than mainstream inflation gauges reveal. US military adventurism is hitting Americans hard. AIER’s proprietary Everyday Price Index (EPI) vaulted 2.5 percent to 307.4 in March 2026, its second-largest monthly increase back to January 2020 (the first was an increase of 2.9 percent in March 2022). Of the 24 price categories that compose the EPI, fourteen rose, two were unchanged, and eight declined. Unsurprisingly, the largest jumps in price occurred in motor fuel, housing fuels and utilities, and food away from home. Prescription drugs, internet services, and food at home declined the most. (The juxtaposition of price changes in the food away from home versus food at home categories likely reflects the gasoline pass-through of food delivery service costs.) AIER Everyday Price Index vs. US Consumer Price Index (NSA, 1987 = 100) (Source: Bloomberg Finance, LP) The US Bureau of Labor Statistics (BLS) released Consumer Price Index (CPI) data for March 2026 on April 10, 2026. Headline inflation rose 0.9 percent over the past month, meeting survey expectations. Core inflation rose 0.2 percent, also meeting forecasts. March 2026 US CPI headline and core month-over-month (2016 – present) (Source: Bloomberg Finance, LP) Consumer prices in March showed a mixed pattern, with food prices flat overall after February’s 0.4 percent gain, as grocery prices slipped 0.2 percent even while restaurant prices continued to edge higher. Within food at home, most major categories softened, led by a 0.6 percent decline in meats, poultry, fish, and eggs — helped by a 3.4 percent drop in egg prices — while cereals, dairy, and nonalcoholic beverages also moved lower; the main exception was fruits and vegetables, which rose 1.0 percent. The dominant story, however, was energy, which surged 10.9 percent on the month, its sharpest increase since 2005, driven by a record 21.2 percent jump in gasoline...